Synergistic immunogenic fusion protein-polysaccharide conjugate
An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided.
1. An immunogenic composition comprising a fusion protein-polysaccharide conjugate, wherein the conjugate consists of a bacterial cell wall polysaccharide conjugated to a cancer antigen:PdT fusion protein, where PdT is a nonhemolytic variant of pneumolysin and the cancer antigen is a target protein, wherein administration of the composition to a subject elicits humoral immunity and T-cell immunity or mucosal immunity to the cancer antigen.
2. An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a bacterial cell wall polysaccharide conjugated to a X:Pdt fusion protein where PdT is a nonhemolytic variant of pneumolysin and X is a target protein, such that immunity to X is enhanced, and wherein the polysaccharide is a cancer antigen.
3. An immunogenic composition comprising a fusion protein of a truncated pneumococcal PsaA protein and a nonhemolytic pneumolysin PdT protein, conjugated to a bacterial cell wall polysaccharide (CWPS).
4. The immunogenic composition of claim 1 , wherein the nonhemolytic variant of pneumolysin is connected to the cancer antigen by a linker.
5. The immunogenic composition of claim 4 , wherein the linker is a peptide linker or 1-cyano-4-dimethylaminopyridinium tetrafluororoborate (CDAP).
6. The immunogenic composition of claim 1 , wherein the polysaccharide has a molecular mass of less than 500 kDa.
7. The immunogenic composition of claim 6 , wherein the polysaccharide has a molecular mass of less than 70 kDa.
8. The immunogenic composition of claim 1 , wherein the bacterial cell wall polysaccharide (CWPS) is a pneumococcal polysaccharide or a polysaccharide of prokaryotic or eukaryotic origin.
9. The immunogenic composition of claim 3 , wherein the bacterial cell wall polysaccharide (CWPS) is a pneumococcal polysaccharide or a polysaccharide of prokaryotic or eukaryotic origin.